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Objectives: to study the influence of tobacco exposure and sympathectomy on basal sympathoadrenal function of patients
with Buerger's disease.
Design: plasma catecholamines were measured before and after smoking, in patients with Buerger's disease (n 13), in
patients with Buerger's disease submitted to surgical bilateral lumbar sympathectomy (n 13), and in healthy volunteers
(n 16).
Materials and Methods: venous blood samples were collected before and 2 h after smoking one cigarette (0.9 mg nicotine).
Plasma concentrations (pg/ml) of dihydroxiphenylalanine (pL-DOPA), noradrenalin (pNA), adrenalin (pAD) and
3,4-dihydroxiphenylacetic acid (pDOPAC) were determined.
Results: Buerger's patients have low basal plasma catecholamines compared to volunteers: pNA (501 (196±927) vs
1858 (968±3663)) and pAD (71 (31±109) vs 193 (116±334)). Sympathectomy increased pL-DOPA, pAD and
pDOPAC, but not pNA. After smoking, pNA only decreased in volunteers (1858 (968±3663) vs 1064 (535±2393)). In
Buerger sympathectomy group, smoking lowered pAD (700 (58±3379) vs 278 (54±429)).
Conclusions: in Buerger's disease there is an impairment of sympathoadrenal function with an altered peripheral
adrenergic response to cigarette smoking. Patients submitted to sympathectomy have high pAD, but this benefit is reversed
after smoking. This might be clinically relevant given the association between cigarette smoking and the manifestations of
Buerger's disease and the controversy on the effectiveness of sympathectomy in the management of the disease.
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The aetiology of Buerger's disease or thromboangiitis
obliterans is still unknown.1±4
However, there is compelling evidence for peri-
pheral vessel neurohumoral dysfunction in patients
with Buerger's disease. There is an impairment of
endothelium-dependent vasorelaxation,5 and peri-
pheral sympathetic outflows are known to be
decreased.6,7 Furthermore, there is an intimate clinical
association between cigarette smoking and the mani-
festations of the disease.8±13 In fact, smoking acutely
increases sympathetic drive to muscle blood vessels,
to skin and to the heart,14 and passive smokingPlease address all correspondence to: R. Roncon-Albuquerque,
ServicËo de Angiologia e Cirurgia Vascular da Faculdade de
Medicina do Porto, Al. Prof. HernaÃni Monteiro; 4200 Porto,
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1078±5884/02/040338 06 $35.00/0 # 2002 Elsevier Science Ltd. Alimpairs endothelium-dependent arterial and vein
dilatation.15,16 Additionally, surgical sympathectomy
is one therapeutic approach in the management of
Buerger's disease, although its effectiveness remains
unclear.17±19
Recently, Marder and Mellinghoff20 suggested that
cocaine use could predispose to a vascular occlusive
disease that mimics Buerger's disease. As cocaine is a
powerful sympathomimetic agent,21 the proposed
pathogenic association between its recreational use
and the development of Buerger's disease is an add-
itional argument to a peripheral adrenergic system
involvement in this disease.
In this context, the main objectives of the present
investigation are to study, in patients with Buerger's
disease: (a) the basal sympathoadrenal function
through measurements of plasma catecholamines; (b)
the effects of cigarette smoking on circulating cat-
echolamine levels; (c) the influence of surgical sym-
pathectomy in the management of this disease.l rights reserved.
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The experimental protocol conforms the principles
outlined in the Declaration of Helsinki and was
approved by the ethics committee at the Hospital de
S. JoaÄo ± Faculty of Medicine of Porto (Portugal). All
participants provided written informed consent.
Subjects and experimental protocol
In our personal series of 192 cases,8 the diagnosis of
Buerger's disease was established after Shionoya's
criteria.22 Lumbar sympathectomy by retroperitoneal
approach was performed in 111 patients, of which 40
were bilateral. As one of the main goals of the study
was to evaluate the impact of sympathetic nervous
system peripheral blockade in Buerger's disease, we
only selected patients submitted to bilateral surgical
sympathectomy. Of these 40 patients, 13 were random-
ly selected during their annual follow-up evaluation.
In every patient the `` reactive hyperaemia'' and `` deep
breath'' tests were positive at the time of the study,
indicating effectiveness of lumbar sympathectomy.
For comparison, we selected 13 other patients at
random with Buerger's disease not submitted to
surgical sympathectomy. All Buerger patients were
clinically stable (Table 1).
Finally, a group of 16 healthy volunteers without
peripheral arterial disease (including Buerger's
disease) was identified: (a) all atherosclerosis risk
factors studied were negative: hypertension (blood
pressure5 130/85 mmHg), diabetes mellitus (fasting
blood glucose5 7.0 mmol/l), dislipidaemia (fasting
profile: total cholesterol5 5.2 mmol/l, triglycerides5
1.7 mmol/l, HDL-cholesterol4 1.04 mmol/l, LDL-
cholesterol5 3.4 mmol/l) and obesity (body mass
index between 18.5 and 24.9); (b) hypercoagulability
states were excluded: protein C deficiency, protein S
deficiency, antithrombin III deficiency, antiphospholi-
pid antibodies; (c) there were no clinical symptoms of
peripheral arterial disease; (d) the physical examin-
ation did not reveal trophic lesions of the extremities;
(e) the ankle±brachial index (ABI) was 41.0.
The smoking status of healthy volunteers was
assessed during a brief interview by using a struc-
tured questionnaire. In patients with Buerger's dis-
ease, the smoking status was evaluated by their
clinical follow-up records and confirmed after the
same structured questionnaire. All subjects studied
had no smoking habits in the last 12 months, evalu-
ated through the same structured questionnaire.
Venous blood samples (20 ml) were collected
blindly during the morning (first sample between8.00 and 8.30 a.m.) from an antecubital vein, before
and 2 h after smoking. The subjects smoked one cig-
arette (0.9 mg nicotine) in a closed room, and had no
caffeine or food intake in the previous 12 h. All med-
ications were suspended in the previous 15 days. This
methodology has been previously shown to reliably
increase plasma concentrations of nicotine until 2 h
after smoking.23 Therefore, we studied the effects of
sustained elevated plasma nicotine levels.
We determined plasma concentrations of: (1) nor-
adrenalin (pNA), the primary neurotransmitter
released from postganglionic sympathetic nerve
endings; (2) adrenalin (pAD), the primary neuro-
transmitter released from the adrenal medulla; (3)
dihydroxiphenylalanine (pL-DOPA), the precursor
of endogenous catecholamines and the immediate
product of the rate-limiting enzymatic step in catecho-
lamine biosynthesis; and (4) 3,4-dihydroxiphenylacetic
acid (pDOPAC), a catecholamine metabolite.
Assay of L-DOPA, NA, AD and DOPAC
Plasma concentrations of L-DOPA, NA, AD and
DOPAC were quantified by means of high pressure
liquid chromatography (HPLC) with electrochemical
detection, as previously reported.24 The high pressure
liquid chromatograph system consisted of a pump
(Gilson model 302; Gilson Medical Electronics, Villiers
le Bel, France) connected to a manometric module
(Gilson model 802 C) and a stainless-steel 5 mm ODS
column (Biophase; Bioanalytical Systems, West
Lafayette, IN) of 25 cm length; samples were injected
by means of an automatic sample injector (Gilson
model 231) connected to a Gilson dilutor (model
401). The mobile phase was a degassed solution of
citric acid (0.1 mM), sodium octylsulphate (0.5 mM),
sodium acetate (0.1 M), EDTA (0.17 mM), dibuty-
lamine (1 mM) and methanol (8% v/v), adjusted to
pH 3.5 with perchloric acid (2 M) and pumped at a
rate of 1.0 ml/min. The detection was carried out elec-
trochemically with a glassy carbon electrode, an Ag/
AgCl reference electrode and an amperometric detect-
or (Gilson model 141); the detector cell was operated
at 0.75 V. The current produced was monitored using
the Gilson 712 HPLC software. The lower limits for
detection of pL-DOPA, pNA, pAD and pDOPAC
ranged from 350 to 500 fmol.
Statistical analysis
Age, age at first symptom and duration of the disease
in the studied population were analysed by the
Mann±Whitney rank sum test. In Table 1, proportionsEur J Vasc Endovasc Surg Vol 24, October 2002
Table 1. Clinical features of patients with Buerger's disease at the
time of observation.
Buerger
n (%)
Buerger
sympathectomy
n (%)
Phlebitis 2 (25) 4 (36)
Claudication 2 (25) 3 (27)
Ulcer 1 (12) 0 (0)
Necrosis 0 (0) 0 (0)
Rest pain 0 (0) 0 (0)
By-pass surgery 0 (0) 1 (9)
Minor amputations 0 (0) 1 (9)
Major amputations 0 (0) 0 (0)
There are no statistical significant differences between Buerger and
Buerger sympathectomy groups.
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Fig. 1. Basal levels of plasma L-DOPA, NA, AD and DOPAC.
Patients in Buerger group presented low basal values of pL-DOPA,
pNA, pAD and pDOPAC, compared with volunteers group. In
Buerger sympathectomy group, basal pL-DOPA, pAD and pDO-
PAC but not pNA are augmented, when compared with Buerger
group. Data is presented as median (5th±95th percentile).  p5 0.05
vs volunteers group; { p5 0.05 vs Buerger group.
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Fig. 2. Cigarette smoking and NA plasma concentrations. Two hours
after smoking, only volunteers group had a fall in NA serum con-
centration. In Buerger group smoking slightly increased pNA, while
in Buerger sympathectomy group smoking had no significant
effect on pNA. Data is presented as median (5th±95th percentile). p5 0.05 vs before smoking and { p5 0.05 vs volunteers.
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Fig. 3. Effect of tobacco exposure on AD plasma concentrations of
patients with Buerger's disease submitted to bilateral surgical lum-
bar sympathectomy. Two hours after smoking one cigarette, patients
of Buerger sympathectomy group had a significant fall in pAD.
Data is presented as median (5th±95th percentile).  p5 0.05 vs
before smoking.
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and 3 paired data was analysed by the Wilcoxon
signed rank test, while unpaired data was analysed
by the Mann±Whitney rank sum test. The correlations
pNA/(time of disease) and pNA/(post-SLS period)
(Fig. 4) were analysed by simple regression. Results
are expressed as median and range (median (min±
max)), in pg/ml of plasma. p5 0.05 was considered
significant.
Results
Baseline characteristics of the studied population
Volunteers were younger compared to Buerger
and Buerger sympathectomy groups (28 (19±57)Eur J Vasc Endovasc Surg Vol 24, October 2002volunteers vs 42 (23±56) Buerger vs 48 (33±57)
Buerger sympathectomy; years). However, there
was no significant difference of age between the
disease groups. In these groups, average age at
first symptom (31 (20±40) Buerger vs 32 (26±47)
Buerger sympathectomy; years) and duration of
the disease (11 (1±19) Buerger vs 14 (1±22) Buerger
sympathectomy; years) were similar.
Clinical features at time of observation of patients
in Buerger and Buerger sympathectomy groups
were analogous (Table 1). In fact, there were no
significant differences between the disease groups
in the proportion of phlebitis, claudication, ulcers,
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Fig. 4. Plasma NA in disease evolution of Buerger and Buerger sympathectomy groups. In Buerger group, pNA does not correlate with
time of disease (left), suggestting that pNA are stable during the evolution of the disease. This is in contrast with Buerger sympathectomy
group, where pNA was inversely correlated with the post-sympathectomy period (right).
Plasma Catecholamines in Buerger's Disease 341necrosis, rest pain, by-pass surgeries, minor and major
amputations.
Basal levels of plasma catecholamines
Buerger group presented low basal pNA (501 (196±
927) Buerger vs 1858 (968±3663) volunteers) and pAD
(71 (31±109) Buerger vs 193 (116±334) volunteers).
This was in accordance with lower pL-DOPA and
pDOPAC in this group (Fig. 1).
Cigarette smoking and plasma catecholamines
In patients with Buerger's disease, cigarette smoking
had distinct effects in plasma catecholamines, when
compared with volunteers. In fact, smoking decreased
pNA in volunteers group (from 1858 (968±3663) to
1064 (535±2393)), but slightly increased pNA concen-
trations in Buerger group (from 501 (196±927) to 557
(215±1038)) (Fig. 2). In Buerger sympathectomy
group smoking did not change significantly pNA
two hours after smoking (Fig. 2). In the disease
groups, smoking had distinct effects on pAD: in
Buerger group there was no significant difference,
but in Buerger sympathectomy group there was
a pronounced fall in pAD (700 (58±3379) before
smoking vs 277 (54±429) after smoking) (Fig. 3). In all
groups smoking did not alter significantly pL-DOPA
and pDOPAC.Surgical lumbar sympathectomy and
plasma catecholamines
Buerger sympathectomy group had higher basal
pAD (700 (58±3379) vs 71 (31±109)) but similar pNA,
compared with Buerger group (Fig. 1). This is in
accordance with the higher basal pL-DOPA and pDO-
PAC in Buerger sympathectomy group (Fig. 1).
Interestingly, there was an inverse correlation between
pNA and the post-sympathectomy period (r 0.80
with p 0.003) (Fig. 4). This differs from the Buerger
group, where pNA is not dependent on the duration
of disease (r 0.09 with p 0.79) (Fig. 4).
Conclusions
The present study shows that patients with Buerger's
disease have low basal plasma catecholamines. As
volunteers were younger and since sympathoadrenal
function changes with ageing,25 these differences
require further consideration. Plasma NA concentra-
tions have been reported to increase 10±15% per
decade over the adult age range, especially when
obtained from arterial rather than venous blood.26±28
Other studies have not found such increases.29±32 In
the present study, the decrease in pNA observed in the
Buerger group may well have been even higher if the
volunteers and Buerger groups were matched for age.
Regarding pAD, investigations to date have found
slightly lower or no changes across the adult age
range.33,34 Therefore, the decrease in pAD described
in Buerger group could be due, only in part, toEur J Vasc Endovasc Surg Vol 24, October 2002
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group. Taken together, these evidences support our
finding of low basal plasma concentration of catecho-
lamines in Buerger's disease. This could be due either
to decreased production or to increased metabolism
and/or excretion. As previous reports describe a
decreased basal sympathetic muscle and skin neural
outflows in Buerger's disease,6,7 it is likely that there is
depressed sympathoadrenal function.
We also demonstrated an altered peripheral adre-
nergic response to cigarette smoking in patients with
Buerger's disease. In healthy controls, nicotine most
likely contributed to the smoking induced pNA fall:
(a) there are still high levels of plasma nicotine two
hours after smoking;23 (b) after an initial period of
stimulation, nicotine depresses sympathetic neuro-
transmission.35,36 In Buerger and Buerger sympath-
ectomy groups, there was no fall in pNA which could
indicate that, in this disease, there is an attenuation of
the sympathetic inhibitory action of nicotine. This
would result in higher pressor cardiovascular effects
of cigarette smoking, since there is experimental
evidence that this effect is mainly dependent on NA
induced peripheral a-adrenergically-mediated vaso-
constriction.37 This might contribute, at least in part,
to the clinical association between cigarette smoking
and Buerger's disease.
In our study, pNA were similar in Buerger and
Buerger sympathectomy groups. This is apparently
in contradiction with experimental data on animals
where sympathectomy decreased NA levels.38 How-
ever, it should be noted that in sympathectomised
patients pNA was inversely correlated with the post-
sympathectomy period, suggesting that its efficacy
increases with time (Fig. 4). Surgical sympathectomy
increased pAD, and these patients had concomitant
higher pL-DOPA and pDOPAC. This suggests that
surgical sympathectomy may have a stimulatory
effect on adrenal medullary function. This may allow
Buerger's disease patients to have higher pAD/pNA
ratios, with enhanced basal vasodilatation, since AD
has a lower vasoconstrictor effect than NA.39 How-
ever, it should be noted that this increase in pAD was
strongly attenuated after smoking.
In conclusion, our data confirms that in Buerger's
disease there is an impairment of sympathoadrenal
function, with lower basal plasma catecholamines
and an altered peripheral adrenergic response to cig-
arette smoking. We also demonstrate that surgical
sympathectomy increases pAD, which is reversed
after smoking. This might be clinically relevant given
the strong association between tobacco exposure and
the aetiology of Buerger's disease and the controversy
about the effectiveness of surgical sympathectomy inEur J Vasc Endovasc Surg Vol 24, October 2002the management of this disease. In this context, our
observations suggest that, in this disease, nicotine has
a higher pressor cardiovascular effect and that surgi-
cal sympathectomy, promoting vasodilatation through
increased pAD/pNA ratios, might be useful in the
management of Buerger's disease. However, the use-
fulness of surgical sympathectomy seems to be
dependent on smoking cessation, since smoking
decreases pAD. This is in accordance with the clinical
observation that, at present, the only proven strategy
to prevent progression of the disease and avoid ampu-
tations is the complete discontinuation of cigarette
smoking or other use of tobacco in any form.9,19,40
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